

-This application is a continuation-in-part of U.S. Application Serial No.

09/449,914, filed on December 2, 1999, now U.S. Patent No. 6,235,718, issued May

22, 2001, which is a divisional of U.S. Patent No. 6,013,633, issued January 11, 2000.

Please delete the paragraph of the specification beginning at page 7, line 1 and replace it with the following rewritten paragraph:

-U.S. Pat. No. 5,328,899, Boublik *et al.*, issued Jul. 12, 1994, discloses

NPY peptide analogs. Human Neuropeptide Y (NPY) has the formula: H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro- Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile- Thr-Arg-Gln-Arg -Tyr-NH₂ (SEQ ID NO:1). Porcine and rat NPY have the same sequence except for Leu instead of Met in the 17-position. Porcine PYY is homologous having 11 different residues. NPY analogs and N-terminally-shortened fragments, e.g. NPY(18-36), which contain one or more specific D-isomer substitutions for the naturally occurring residues (as well as pharmaceutically acceptable salts thereof), dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, including humans, to substantially lower blood pressure over an extended period of time or to counteract hypertension.

Please delete the paragraph of the specification beginning at page 9, line 13 and replace it with the following rewritten paragraph:

-A1 is a D or L-amino acid selected from the group consisting of Cys,

Leu, Dap (1,2-Diaminopropionic acid), Trp, Gln, a tethered amino acid with an indole ring (e.g., N-Me-Trp), Phe, Hyp, any Trp derivative (e.g., 2 chlorotryptophan, or Tcc);

CaMe-Trp, CaMe-Gln, Des-amino-Trp, Pyr (Pyroglutamic acid), Bth, Nal, Tcc, Asn, Nva,

Abu, Tyr, Tic-OH, Phe, Tip (1,2,3,4-tetrahydronorharman-3-carboxylic acid), and Dip;

AB
Conclude

Please delete the paragraph of the specification beginning at page 10,
line 10 and replace it with the following rewritten paragraph:

Preferred compounds of formula (I) include those in which A1 is [Try] Trp
or a pharmaceutically acceptable salt thereof.

A4

Please amend page 38, line 34 of the specification to read:

39. (Ac-Cys-Trp-Arg-Tyr-NH₂)₂ (SEQ ID NO: 2)

AB

Please amend page 38, line 36 of the specification to read:

41. Dap-Ile-Trp-Arg-Glu-Arg-Tyr-NH₂ (SEQ ID NO: 3)

A6

Please amend page 38, line 37 of the specification to read:

42. Leu-Ile-Trp-Arg-Glu-Arg-Tyr-NH₂ (SEQ ID NO: 4)

A7

Please amend page 38, line 38 of the specification to read:

43. Cyclo(-Trp-Arg-Nva-Arg-Tyr-) (SEQ ID NO: 5)

AB

Please add enclosed pages 46 and 47 and renumber previous page 46 to
read 48.